Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q4 2019 · 10-K
Revenue$27.00M$27.00M−54.7% vs Q4 2018 Net Income-$7.37M-$7.37MN/M vs Q4 2018 EPS Diluted-$0.43-$0.43N/M vs Q4 2018 Operating Incomederived-$10,179,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,339,000N/M Margins · derivedOperating margin-37.7%−93.3 pt vs Q4 2018
Net margin-27.3%+44.0 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 27, 2020 · 58 d after period end